Prevents Pneumocystis jirovecii pneumonia (PCP). Sold as Mepron. Every FDA application for this active ingredient: 2 branded and 9 generic.
As of Nov 16, 2026, FDA lists 11 applications for Atovaquone (sold as Mepron), first approved Nov 25, 1992, with 1 new use approved and 0 published complete response letters.
| Atovaquone | Part D | $40.3M | -2% | 31,810 |
| Mepron | Part D | $211K | -16% | 33 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma · Merck Sharp & Dohme LLC | Phase 2 / Phase 3 | Not yet recruiting | Nov 5, 2026 |
| Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)Pneumocystis, Pneumocystis Infection · McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 4 | Not yet recruiting | Jan 21, 2026 |
| Atovaquone Combined With Radiation in Children With Malignant Brain TumorsHigh-grade Glioma, Medulloblastoma · Emory University | Phase 1 | Recruiting | Oct 3, 2024 |
| Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian CancerOvarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma · Emory University | Phase 2 | Recruiting | Aug 18, 2023 |
| Nov 25, 1992 | MepronNDA 20259 · New molecular entity | Glaxosmithkline LLC | 0 | Discontinued |
| Feb 8, 1995 | MepronNDA 20500 · New dosage form | Glaxosmithkline LLC | 12 | Marketed |
| Mar 18, 2014 | AtovaquoneANDA 202960 | Amneal Pharms | 5 | Marketed |
| Apr 28, 2017 | AtovaquoneANDA 207833 | Chartwell Rx | 2 | Marketed |
| Oct 11, 2017 | AtovaquoneANDA 209750 | Apotex | 4 | Discontinued |
| Sep 11, 2018 | AtovaquoneANDA 209105 | Lupin | 2 | Discontinued |
| Oct 11, 2018 | AtovaquoneANDA 210692 | Hetero Labs Ltd Iii | 2 | Marketed |
| Nov 21, 2018 | AtovaquoneANDA 209685 | Glenmark Speclt | 3 | Marketed |
| May 31, 2019 | AtovaquoneANDA 210510 | Abhai LLC | 2 | Marketed |
| Mar 30, 2021 | AtovaquoneANDA 212918 | Bionpharma | 1 | Marketed |
| Oct 25, 2021 | AtovaquoneANDA 214272 | Pai Holdings | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA